Status:
COMPLETED
Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Atrial Fibrillation
Catheter Ablation
Eligibility:
All Genders
18-100 years
Brief Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Catheter ablation using pulmonary vein isolation (PVI) in an established treatment strategy for AF. Pulsed Field Ablation (PFA...
Detailed Description
Pulmonary vein isolation represents the cornerstone of AF ablation. PFA is a novel non-thermal cardiac ablation modality which is currently studied in clinical trials for the treatment of AF with prom...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients with paroxysmal AF referred for first-time catheter ablation using PFA or RFA
- Non-opposition to participate
Exclusion
- Age \< 18 years
- Persons under judicial protection (guardianship, guardianship) or deprived of freedom
- Prior left atrial ablation
- Prior cardiac surgery comprising incision of the left atrium
- Prior myocardial infarction or stroke in the previous 30 days
- Acute or chronic inflammatory state: active smoking, auto-immune disease, active tumor disease, myocarditis
- Antiplatelet therapy (e.g. aspirine, clopidogrel) within the 7 last days
- Anti-inflammatory treatment (e.g. glucocorticoids, colchicine, cyclophosphamide, azathioprine, mycophenolic acid, antibodies) within the 7 last days
Key Trial Info
Start Date :
October 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 25 2025
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT06160076
Start Date
October 16 2023
End Date
April 25 2025
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Haut-Lévèque
Pessac, France, 33604